TUNE THERAPEUTICS
Tune Therapeutics strives to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases.
TUNE THERAPEUTICS
Industry:
Biotechnology
Founded:
2020-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.tunetx.com
Total Employee:
51+
Status:
Active
Contact:
98102-3788
Total Funding:
40 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network
Similar Organizations
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Omega Therapeutics
Omega Therapeutics offers a proprietary epigenomic programming platform.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hatteras Venture Partners
Hatteras Venture Partners investment in Series A - Tune Therapeutics
Saisei Ventures
Saisei Ventures investment in Series A - Tune Therapeutics
New Enterprise Associates
New Enterprise Associates investment in Series A - Tune Therapeutics
Mission BioCapital
Mission BioCapital investment in Series A - Tune Therapeutics
Emerson Collective
Emerson Collective investment in Series A - Tune Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-04-10 | Tune Therapeutics Strengthens Leadership Team with Addition of Dr. Derek Jantz as Chief Scientific Officer and Zachary Hale as General Counsel |
Official Site Inspections
http://www.tunetx.com Semrush global rank: 3.29 M Semrush visits lastest month: 4.31 K
- Host name: 199.16.172.224
- IP address: 199.16.172.224
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tune Therapeutics"
Careers - Tune Therapeutics
If you are seeking to verify the authenticity of a job posting, Tune Careers contains the official list of all open positions. If a position is not listed here, then we are not currently hiring for it. We …See details»
Tune Therapeutics - Crunchbase Company Profile
Tune Therapeutics strives to develop paradigm-changing cell and gene therapies that leverage epigenetic programming for the treatment of devastating diseases.See details»
John McHutchison - Tune Therapeutics
John McHutchison AO, MD is a Board Member at Tune Therapeutics, and former President and CEO of Assembly Biosciences. At Assembly, he led the company’s progress in the anti-viral space before transitioning to the board of directors …See details»
Tune Therapeutics | LinkedIn
Tune Therapeutics | 13,020 followers on LinkedIn. Mastering the epigenome, unlocking complex disease. | The vast majority of human disease is governed by the epigenome, the subtle …See details»
Tune Therapeutics Names John McHutchison as CEO and …
NOTE: Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles …See details»
Tune Therapeutics Names John McHutchison as CEO and …
Mar 4, 2025 DURHAM, N.C. & SEATTLE, March 04, 2025--Leading epigenome company Tune Therapeutics is proud to announce that veteran drug-development executive John …See details»
Duke Capital Partners
May 22, 2023 NOTE: Tune Therapeutics is a Duke University start-up developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).Duke Fuqua alum Matt Kane is CEO and Duke …See details»
Tune Therapeutics | North Carolina Biotech Center
Tune Therapeutics develops novel cell and gene therapy products with their epigenome editing and gene regulation platform, TEMPO.See details»
Tune Therapeutics Receives Approval to Initiate Clinical Trial in …
Jan 7, 2025 DURHAM, N.C. & SEATTLE, January 07, 2025--Leading epigenetic therapy company Tune Therapeutics announced today that it will begin a clinical trial in Hong Kong …See details»
Tune Therapeutics to test vaccine-like epigenetics …
Apr 30, 2024 Duke University spinout Tune Therapeutics is rehearsing the overture of its avant-garde therapeutic platform targeting chronic Hepatitis B Virus (HBV) that could also upend many more chronic disease treatments.Tune, …See details»
Tune Therapeutics – Tune Therapeutics Receives Approval to …
Jan 7, 2025 According to the World Health Organization, the burden of Hepatitis infection is highest in the Western Pacific Region – including China, Japan, Cambodia, New Zealand, and …See details»
Tune Therapeutics首次提供数据支持Tune-401：一种一流的乙型肝 …
Dec 6, 2023 TUNE-401 represents a fundamentally new approach to HBV treatment, in that it utilizes Tune’s precision genetic tuning platform, TEMPO, to inactivate viral DNA integrated …See details»
Tune Therapeutics on LinkedIn: #tunetx #epigenetics
No coast rivalries here—just collaboration! The Tune team came together in Durham from across the country, bringing energy and inspiration. #tunetx…See details»
Tune Therapeutics Receives Approval to Initiate Clinical ... - BioSpace
Jan 7, 2025 The company’s leading therapeutic candidate, Tune-401, has now been approved for clinical trials in both Hong Kong and New Zealand DURHAM, N.C. & SEATTLE- …See details»
全新疗法！直接靶向整合HBV DNA和cccDNA的表观遗传编辑疗 …
Mar 15, 2024 具体数据查看（HEPDART_Dec5_Web.pdf (tunetx.com)） 此外，这些结果是通过单一靶序列实现的，该序列在细胞内的所有病毒环境和位置中都是通用的，并且在不同的 …See details»
Tune Therapeutics – Tune Therapeutics Launches with Pioneering ...
World-leading researchers and venture-builders found company to mine the new frontier of epigenomics and unlock complex disease. Novel approach tunes and calibrates gene …See details»
TONEX Editor - IK Multimedia
The free editor features a new floating window design for better screen organization, enabling seamless browsing of Tone Models, amps, cabs, custom IRs and VIR. You can directly access …See details»
10 Organizational Issues (With Causes and Solutions)
Sep 9, 2024 To promote innovation and creativity in the organization, you can encourage employees to think differently, discuss new ideas, implement fresh strategies, and experiment. …See details»
News & Insights - Tune Therapeutics
Mar 4, 2025 Get the latest news about genetic therapies through epigenomic control – from targeting a limited range of rare conditions to overcoming thousands of complex and chronic …See details»
Tune Therapeutics – Tune Therapeutics Moves into Clinical …
TUNE-401 will be the first epigenetic therapy to enter clinical trials for an infectious disease. DURHAM, NC and SEATTLE, WA (November 14, 2024) – Leading epigenome editing …See details»